Itraconazole

General:

Itraconazole is a third generation synthetic antimycotic drug of the triazolimidazole type. Its structure consists of a triazole ring system with a lipophilic end. The drug has a lipophilic character with almost complete protein binding and a plasma half-life of approx. 17 hours. Itraconazole inhibits the synthesis of the substance ergosterol, which is an important component of the cell membranes of fungi. As a consequence, a disturbance of cell membrane formation occurs. Itraconazole is applied systemically in fungal infections, which are resistant to local treatment with creams, solutions or powders. These can be infections with dermatophytes or with Malassezia furfur (pityriasis versicolor), infections of finger and toe nails. Itraconazole is biotransformed via cytochrome P450. A systemic treatment in pregnant or breastfeeding women with itraconazole is contraindicated.

Indication:	Therapy monitoring in fungal infections
Material:	1 ml serum
TAT:	2 weeks*
Method:	LCMS
Units:	mg/L
Ref.- range:	>0.5 - 1.0

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit http://www.fml-dubai.com/parameter-listings/

Updated 01/02/2022